- HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event2011 | First Faculty of Medicine
- Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study2013 | First Faculty of Medicine
- Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study2014 | First Faculty of Medicine
- Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event2013 | First Faculty of Medicine
- Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS2021 | Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice2017 | First Faculty of Medicine
- Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis2021 | First Faculty of Medicine
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome2012 | First Faculty of Medicine
- Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis2013 | First Faculty of Medicine
- Association of Pregnancy With the Onset of Clinically Isolated Syndrome2020 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment 16401Publication without faculty affiliation
- Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients2015 | First Faculty of Medicine
- Early magnetic resonance imaging predictors of clinical progression after 48months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a2015 | First Faculty of Medicine
- Treatment possiblities of multiple sclerosis in children and adolescents2019 | Faculty of Medicine in Pilsen
- Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients2017 | First Faculty of Medicine
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?2017 | First Faculty of Medicine
- Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients2017 | First Faculty of Medicine
- Pathological cut-offs of global and regional brain volume loss in multiple sclerosis2019 | First Faculty of Medicine
- A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study2017 | First Faculty of Medicine
- Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis2020 | First Faculty of Medicine
- Repeated subcutaneous injections of IL12/23 P40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study2008 | Second Faculty of Medicine